Top

18-08-2017 | Ankylosing spondylitis | Review | Article

Urolithiasis as an extraarticular manifestation of ankylosing spondylitis

Journal: Rheumatology International

Authors: Cengiz Korkmaz, Döndü Üsküdar Cansu, John A. Sayer

Publisher: Springer Berlin Heidelberg

Abstract

Ankylosing spondylitis (AS) affects sacroiliac and axial joints as well as extraarticular organs, such as the eye, lung, bowel, and heart. Although examples of renal involvement in AS, such as IgA nephropathy, amyloidosis, and glomerulonephritis, have been reported, it has not been emphasized that urolithiasis is frequently formed in the clinical course of AS. Growing evidence indicates that urolithiasis may be observed in AS patients and is more frequent than other extraarticular features. In this review, we will discuss frequency and predictors of AS-related urolithiasis and summarize the possible underlying genetic and biochemical mechanisms. We believe an increased awareness of urolithiasis as a complication of AS will encourage future studies that will shed light on disease mechanisms and preventative therapies.

Van der Heijde D (2008) Ankylosing spondylitis. In: Klippel JH, Stone JH, Crofford LJ, White PH (eds) Primer on the rheumatic disease, 13th edn. Springer, Berlin

Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(Suppl 3):8–18CrossRef

El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560CrossRefPubMed

Elewaut D, Matucci-Cerinic M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology 48:1029–1035CrossRefPubMed

Korkmaz C, Ozcan A, Akçar N (2005) Increased frequency of ultrasonographic findings suggestive of renal stones in patients with ankylosing spondylitis. Clin Exp Rheumatol 23:389–392PubMed

Jakobsen AK, Jacobsson LT, Patschan O, Askling J, Kristensen LE (2014) Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS ONE 25:9

Lui NL, Carty A, Haroon N, Shen H, Cook RJ, Inman RD (2011) Clinical correlates of urolithiasis in ankylosing spondylitis. J Rheumatol 38:1953–1956CrossRefPubMed

Jakobsen AK, Jacobsson LT, Patschan O, Hopfgarten T, Askling J, Kristensen LE (2015) Surgical interventions for nephrolithiasis in ankylosing spondylitis and the general population. Scand J Urol 21:1–6

Elian N, Berinde L, Georgescu L, Ocica I, Saba I (1972) Nephro-uropathic manifestations in ankylopoietic spondylitis. Med Interna 24:187–193

10.

Mladenovic V (1973) Nephrolithiasis in ankylosing spondylitis. Rheumatizam 20:106–110

11.

Jimenez Balderas FJ, Robles EJ, Juan L, Badui E, Arellano H, Espinosa Said L et al (1989) Purine metabolism in ankylosing spondylitis: clinical study. Arch Invest Med 20:163–170

12.

Incel NA, Gökoğlu F, Nacir B, İncel N (2006) Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin Rheumatol 25:667–670CrossRefPubMed

13.

Canales BK, Leonard SM, Singh JA, Orzano IM, Zimmermann B, Weiland D et al (2006) Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol 20:542–546CrossRefPubMed

14.

Cansu DU, Calışır C, Savaş Yavaş U, Kaşifoğlu T, Korkmaz C (2011) Predictors of radiographic severity and functional disability in Turkish patients with ankylosing spondylitis. Clin Rheumatol 30:557–562CrossRefPubMed

15.

Fallahi S, Jamshidi AR, Gharibdoost F, Mahmoudi M, Paragomi P, Nicknam MH et al (2012) Urolithiasis in ankylosing spondylitis: correlation with BASDAI, BASFI and BASMI. Caspian J Intern Med 3:508–513PubMedPubMedCentral

16.

Resorlu H, Adam G, Aylanc N, Akbal A, Ozdemir H (2015) Prospective evaluation of the renal morphology and vascular resistance inpatients with ankylosing spondylitis. Med Ultrason 17:180–184CrossRefPubMed

17.

Moe OW (2006) Kidney Stones: pathophysiology and medical management. Lancet 367(9507):333–344CrossRefPubMed

18.

Sakhaee K, Maalouf NM, Sinnott B (2012) Kiney Stones 2012:pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97:1847–1860CrossRefPubMedPubMedCentral

19.

Gaspar SR, Mendonça T, Oliveira P, Oliveira T, Dias J, Lopes T (2016) Urolithiasis and crohn’s disease. Urol Ann 8:297–304CrossRefPubMedPubMedCentral

20.

Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542–1551PubMed

21.

Pang SW, Davis JC (2006) Clinical aspects of ankylosing spondylitis. In: Weisman MH, Reveille JD, Van der Heijde D (eds) Ankylosing spondylitis and spondyloarthropathies, 1st edn. Mosby, Philadelphia, pp 145–153

22.

Mielants H, van den Bosch F (2006) Inflammatory bowel disease spondyloarthritis: epidemiology, clinical features, and treatment. In: Weisman MH, Reveille JD, Van der Heijde D (eds) Ankylosing spondylitis and spondyloarthropathies, 1st edn. Mosby, Philadelphia, pp 65–74CrossRef

23.

Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461–1463CrossRefPubMedPubMedCentral

24.

Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP (2008) Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 58:1020–1025CrossRefPubMed

25.

van Sommeren S, Janse M, Karjalainen J, Fehrmann R, Franke L, Fu J, Weersma RK (2014) Extraintestinal manifestations and complications in inflammatory bowel disease: from sharedgenetics to shared biological pathways. Inflamm Bowel Dis 20:987–994PubMed

26.

Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M et al (2014) Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 73:1746–1748CrossRefPubMed

27.

Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP et al (2012) Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 14(6):R261CrossRefPubMedPubMedCentral

28.

Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J (2003) Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52:847–853CrossRefPubMedPubMedCentral

29.

Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA et al (2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 128:2020–2028CrossRefPubMed

30.

Gönüllü E, Bilge NŞ, Cansu DU, Bekmez M, Musmul A, Akçar N et al (2016) Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study. Urolithiasis. doi:10.1007/s00240-016-0911-8 PubMed

31.

Shodjai-Moradi E, Ebringer A, Abuljadayel I (1992) IgA antibody response to Klebsiella in ankylosing spondylitis measured by immunoblotting. Ann Rheum Dis 51:233–237CrossRefPubMedPubMedCentral

32.

Khalafpour S, Ebringer A, Abuljadayel I et al (1988) Antibodies to Klebsiella and Proteus microorganisms in ankylosing spondytitis and rheumatoid arthritis patients measured by ELISA. Br J Rheumatol 27(suppl 2):86–89CrossRefPubMed

33.

Yuan GH, Shi GY, Ding YZ (1993) Antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Zhonghua Nei Ka Za Zhi 32:467–469 (in Chinese, English abstract)

34.

Veys EM, van Laera M (1973) Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis 32:493–496CrossRefPubMedPubMedCentral

35.

Ardiçoğlu O, Atay MB, Ataoğlu H et al (1996) IgA antibodies to Klebsiella in ankylosing spondylitis. Clin Rheumatol 15:573–576CrossRefPubMed

36.

Muñoz-Ortego J, Vestergaard P, Rubio JB, Wordsworth P, Judge A, Javaid MK et al (2014) Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res 29:1770–1776CrossRefPubMed

37.

Maghraoui AE (2004) Osteoporosis and ankylosing spondylitis. Joint Bone Spine 71:291–295CrossRefPubMed

38.

Ou SM, Chen YT, Shih CJ, Tarng DC (2015) Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study. Osteoporos Int 26:1261–1269CrossRefPubMed

39.

Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H (2014) Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 41:1349–1356CrossRefPubMed

40.

Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257–3262CrossRefPubMed

41.

Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, de Oliveira RM, Silva CA, Bonfa E, Pereira RM (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216CrossRefPubMedPubMedCentral

42.

Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931CrossRefPubMed

43.

Gratacós J, Collado A, Pons F, Osaba M, Sanmartí R, Roqué M et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319–2324CrossRefPubMed

44.

Pacifici R (1997) Idiopathic hypercalciuria and osteoporosis—distinct clinical manifestations of increased cytokine induces bone resorption? J Clin Endocrinol Metab 82:29–31PubMed

45.

Will R, Bhalla AK, Palmer R, Ring R, Calin A (1989) Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet II:1483–1485CrossRef

46.

Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjörnsson G et al (2015) Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 14(6):7975CrossRef

47.

Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1997) Family history and risk of kidney stones. J Am Soc Nephrol 8:1568–1573PubMed

48.

Stechman MJ, Loh NY, Thakker RV (2007) Genetics of hypercalciuric nephrolithiasis: renal stone disease. Ann N Y Acad Sci 1116:461–484CrossRefPubMed

49.

Sayer JA (2008) The genetics of nephrolithiasis. Nephron Exp Nephrol 110:e37–e43CrossRefPubMed

50.

Tsui FW, Tsui HW, Cheng EY, Stone M, Payne U, Reveille JD et al (2003) Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 48:791–797CrossRefPubMed

51.

Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW (2005) ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 7(3):R513–R525CrossRefPubMedPubMedCentral

52.

Liu Z, Cui Y, Zhou X, Zhang X, Han J (2013) Association of mineralization-related genes TNAP and ANKH polymorphisms with ankylosing spondylitis in the Chinese Han population. Biosci Trends 7:89–92PubMed

53.

Korkmaz C, Sayer JA (2012) ANKH and renal stone formation in ankylosing spondylitis. J Rheumatol 39:1756CrossRefPubMed

54.

Ho AM, Johnson MD, Kingsley DM (2000) Role of the Mouse ank gene in control of tissue calcification and arthritis. Science 289:265–270CrossRefPubMed

55.

Russell RG (1976) Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum 19(Suppl 3):465–478CrossRefPubMed

56.

Moochhala SH, Sayer JA, Carr G, Simmons NL (2008) Renal calcium stones: insights from the control of bone mineralization. Exp Physiol 93:43–49CrossRefPubMed

57.

Carr G, Sayer JA, Simmons NL (2007) Expression and localisation of the pyrophosphate transporter, ANK, in murine kidney cells. Cell Physiol Biochem 20:507–516CrossRefPubMed

58.

Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Vieira de Sousa E, Pinto P et al (2012) ANKH and susceptibility to and severity of ankylosing spondylitis. J Rheumatol 39(1):131–134CrossRefPubMed

59.

Timms AE, Zhang Y, Bradbury L, Wordsworth BP, Brown MA (2003) Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 48(10):2898–2902CrossRefPubMed

60.

Hess B (1998) Drug-induced urolithiasis. Curr Opin Urol 8:331–334CrossRefPubMed

61.

De Koninck AS, Groen LA, Maes H, Verstraete AG, Stove V, Delanghe JR (2016) Unusual type of kidney stone. Clin Lab 62:235–239CrossRefPubMed

62.

Erturk E, Casemento JB, Guertin KR, Kende AS (1994) Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol 151:1605–1606CrossRefPubMed

63.

Yanagisawa R, Kamijo T, Nagase Y (1999) A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis. Nihon Hinyokika Gakkai Zasshi 90:462–465 (Japanese) PubMed

64.

Russinko PJ, Agarwal S, Choi MJ, Kelty PJ (2003) Obstructive nephropathy secondary to sulfasalazine calculi. Urology 62(4):748CrossRefPubMed

65.

Hoffnung JM, Parker MD, Hartz JW (1982) Papillary necrosis mimicking staghorn calculi. Urology 20:325–327CrossRefPubMed

66.

Boonen A, Everens JL (2002) Ankylosing spondylitis: what is the cost to society and can it be reduced? Best Pract Res Clin Rheumatol 16:691–705CrossRefPubMed

67.

Ben-Ami H, Ginesin YI, Behar DM, Fischer D, Edoute Y, Lavy A (2002) Diagnosis and treatment of urinary tract complication in Crohn’s disease: an experience over 15 years. Can J Gastroenterol 16:225–229CrossRefPubMed

68.

Sato S, Sasaki I, Naito H, Funayama Y, Fukushima K, Shibata C et al (1999) Management of urinary complications in Crohn’s disease. Surg Today 29:713–717CrossRefPubMed

69.

Boussorra H, Sallami S, Said Y, Chebil M, Najjar T (2013) Evaluation of urinary urolithiasis in Crohn’s disease in Tunisian patients. Tunis Med 91:440–443PubMed

70.

Keddis MT, Rule AD (2013) Nephrolithiasis and loss of kidney function. Curr Opin Nephrol Hypertens 22:390–396CrossRefPubMedPubMedCentral

71.

Vupputuri S, Soucie JM, McClellan W, Sandler DP (2004) History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 14:222–228CrossRefPubMed

72.

Akman T, Binbay M, Aslan R et al (2012) Long-term outcomes of percutaneous nephrolithotomy in 177 patients with chronic kidney disease: a single center experience. J Urol 187:173–177CrossRefPubMed

Medicine Matters Rheumatology

Abstract